Scholarlink

Background <p>The association between plasma homocysteine (Hcy) and adverse cardiovascular outcomes in postmenopausal women with coronary heart disease (CHD) remains unclear. This study aimed to investigate the prognostic value of Hcy levels in this high-risk population.</p> Methods <p>We conducted a retrospective cohort study of 624 postmenopausal women with CHD from Ningxia Medical University General Hospital, with a 3-years follow-up. The association between Hcy and major adverse cardiovascular events (MACE) was evaluated using multivariate Cox regression. Non-linear relationships were assessed using generalized additive models (GAM) and threshold effect analyses. Survival disparities were analyzed via Kaplan-Meier estimates. Stratified analyses assessed association robustness, and receiver operating characteristic (ROC) curve analysis determined the predictive capacity of Hcy for MACE risk.</p> Results <p>During follow-up, 133 MACE occurred. Higher Hcy tertiles were associated with increased cumulative MACE risk (log-rank,<i>P</i> &lt; 0.001). The multivariable cox regression revealed a significant positive relationship between Hcy and MACE risk. After full adjustment, each 1 µmol/L increment in Hcy was associated with a 17% increased risk of MACE (HR 1.17, 95%CI:1.12–1.22; <i>P</i> &lt; 0.001). GAM analyses uncovered non-linear relationships (<i>P</i> for non-linearity &lt; 0.05). Threshold analysis identified an inflection point at 11.28µmol/L. Subgroup analyses confirmed the robustness of this association (all <i>P</i> interaction &gt; 0.05). ROC curve analysis demonstrated moderate predictive accuracy for Hcy (AUC 0.729, 95%CI: 0.682–0.777).</p> Conclusion <p>In this retrospective cohort, Hcy may be independently associated with an increased risk of MACE in postmenopausal women with established CHD. These findings may suggest that Hcy could serve as a prognostic biomarker in this high-risk population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma homocysteine and cardiovascular outcomes in postmenopausal women with coronary heart disease: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月15日

查看全文
  • Peng Wu,
  • Zefeng He,
  • Baozhen Zhu,
  • Bo Wu,
  • Yuru Ma,
  • Ru Yan,
  • Tianshui Ma,
  • Jiawei Yang,
  • Ning Yan,
  • Shaobin Jia,
  • Xueping Ma

摘要

Background

The association between plasma homocysteine (Hcy) and adverse cardiovascular outcomes in postmenopausal women with coronary heart disease (CHD) remains unclear. This study aimed to investigate the prognostic value of Hcy levels in this high-risk population.

Methods

We conducted a retrospective cohort study of 624 postmenopausal women with CHD from Ningxia Medical University General Hospital, with a 3-years follow-up. The association between Hcy and major adverse cardiovascular events (MACE) was evaluated using multivariate Cox regression. Non-linear relationships were assessed using generalized additive models (GAM) and threshold effect analyses. Survival disparities were analyzed via Kaplan-Meier estimates. Stratified analyses assessed association robustness, and receiver operating characteristic (ROC) curve analysis determined the predictive capacity of Hcy for MACE risk.

Results

During follow-up, 133 MACE occurred. Higher Hcy tertiles were associated with increased cumulative MACE risk (log-rank,P < 0.001). The multivariable cox regression revealed a significant positive relationship between Hcy and MACE risk. After full adjustment, each 1 µmol/L increment in Hcy was associated with a 17% increased risk of MACE (HR 1.17, 95%CI:1.12–1.22; P < 0.001). GAM analyses uncovered non-linear relationships (P for non-linearity < 0.05). Threshold analysis identified an inflection point at 11.28µmol/L. Subgroup analyses confirmed the robustness of this association (all P interaction > 0.05). ROC curve analysis demonstrated moderate predictive accuracy for Hcy (AUC 0.729, 95%CI: 0.682–0.777).

Conclusion

In this retrospective cohort, Hcy may be independently associated with an increased risk of MACE in postmenopausal women with established CHD. These findings may suggest that Hcy could serve as a prognostic biomarker in this high-risk population.